Zacks: Brokerages Anticipate MEDNAX Inc (NYSE:MD) Will Announce Earnings of $0.90 Per Share

Equities research analysts predict that MEDNAX Inc (NYSE:MD) will post earnings of $0.90 per share for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for MEDNAX’s earnings, with the lowest EPS estimate coming in at $0.88 and the highest estimate coming in at $0.93. MEDNAX posted earnings per share of $0.92 in the same quarter last year, which would suggest a negative year over year growth rate of 2.2%. The company is scheduled to announce its next earnings results before the market opens on Thursday, February 20th.

On average, analysts expect that MEDNAX will report full year earnings of $3.36 per share for the current financial year, with EPS estimates ranging from $3.29 to $3.42. For the next year, analysts expect that the company will post earnings of $3.38 per share, with EPS estimates ranging from $3.20 to $3.48. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that cover MEDNAX.

A number of equities analysts recently commented on the company. Mizuho set a $25.00 price target on MEDNAX and gave the stock a “hold” rating in a report on Friday, November 1st. Stifel Nicolaus upgraded MEDNAX from a “hold” rating to a “buy” rating and upped their price objective for the company from $25.00 to $33.00 in a research note on Thursday, December 12th. TheStreet downgraded MEDNAX from a “c-” rating to a “d” rating in a research note on Friday, November 1st. ValuEngine upgraded shares of MEDNAX from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Finally, Deutsche Bank began coverage on shares of MEDNAX in a report on Friday, January 3rd. They issued a “hold” rating and a $34.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and two have issued a buy rating to the stock. MEDNAX presently has a consensus rating of “Hold” and an average target price of $27.33.

Several institutional investors and hedge funds have recently made changes to their positions in MD. ArrowMark Colorado Holdings LLC raised its position in shares of MEDNAX by 1.2% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 5,352,519 shares of the company’s stock valued at $148,747,000 after buying an additional 63,441 shares in the last quarter. P2 Capital Partners LLC grew its position in MEDNAX by 41.8% during the fourth quarter. P2 Capital Partners LLC now owns 3,900,025 shares of the company’s stock worth $108,382,000 after buying an additional 1,150,025 shares in the last quarter. LSV Asset Management grew its position in MEDNAX by 16.5% during the fourth quarter. LSV Asset Management now owns 1,298,652 shares of the company’s stock worth $36,089,000 after buying an additional 183,857 shares in the last quarter. Bank of New York Mellon Corp grew its position in MEDNAX by 11.5% during the fourth quarter. Bank of New York Mellon Corp now owns 1,231,775 shares of the company’s stock worth $34,232,000 after buying an additional 126,831 shares in the last quarter. Finally, First Trust Advisors LP increased its stake in MEDNAX by 4.0% during the 4th quarter. First Trust Advisors LP now owns 1,016,756 shares of the company’s stock worth $28,256,000 after acquiring an additional 38,834 shares during the period. 87.55% of the stock is currently owned by institutional investors.

Shares of NYSE MD traded down $5.62 during mid-day trading on Friday, hitting $20.97. The company had a trading volume of 181,566 shares, compared to its average volume of 947,871. The company has a market capitalization of $2.25 billion, a PE ratio of -1.20, a price-to-earnings-growth ratio of 1.04 and a beta of 0.84. The firm has a 50-day simple moving average of $26.39 and a two-hundred day simple moving average of $24.52. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 1.35. MEDNAX has a one year low of $19.93 and a one year high of $36.81.

MEDNAX Company Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

See Also: What is Forex?

Get a free copy of the Zacks research report on MEDNAX (MD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.